GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Dynatronics Corp. Reports Operating Results (10-Q)

February 01, 2010 | About:
10qk

10qk

18 followers
Dynatronics Corp. (DYNT) filed Quarterly Report for the period ended 2009-12-31.

Dynatronics Corp. has a market cap of $16.39 million; its shares were traded at around $1.2 with a P/E ratio of 60 and P/S ratio of 0.51.

Highlight of Business Operations:

Net sales were $8,501,437 for the quarter ended December 31, 2009,

compared to $8,718,893 for the quarter ended December 31, 2008. Net sales were

$16,783,900 for the six months ended December 31, 2009, compared to $16,715,042

for the same period in 2008. Despite the difficult economic conditions in the

United States, we were able to maintain sales within 2% of last year's results

for the quarter and we generated a small increase in sales compared to last

year's six months results. Recessionary pressures have resulted in reduced

demand for capital equipment over the past 12 months. However, sales of

manufactured capital equipment for the rehabilitation market experienced a

$287,739 increase in the quarter ended December 31, 2009, compared to the

quarter ended December 31, 2008. That 10% increase in sales of higher margin

manufactured equipment marks the first quarter in the last six quarters that

this category experienced an increase. This is a positive indicator that the

recessionary pressures are starting to abate. This increase was offset by a

$505,195 decrease in sales of medical supplies, treatment tables and aesthetic

products during the quarter ended December 31, 2009. This was an 8% overall

decline in this product category reflecting a sluggish start to the quarter.



Selling, general, and administrative ("SG&A") expenses decreased $128,070,

or 4.5%, to $2,699,357, or 31.8% of net sales, for the quarter ended December

31, 2009, from $2,827,427, or 32.4% of net sales, for the fiscal second quarter

ended December 31, 2008. SG&A expenses decreased $392,348, or 6.8%, to

$5,411,726, or 32.2% of net sales, for the six months ended December 31, 2009,

from $5,804,074, or 34.7% of net sales, for the six months ended December 31,

2008. The decrease in SG&A expenses for the quarter and six months ended

December 31, 2009 is primarily the result of our internal cost reduction

campaign to improve efficiencies. We targeted lowering transaction costs,

obtaining better pricing and terms from service providers, streamlining customer

service and production processes, and improving our sales support functions. The

impact of these changes in SG&A expenses for the quarter ended December 31,

2009, included:



Research and development ("R&D") expenses decreased $58,836, or 22.1%, to

$206,882 for the quarter ended December 31, 2009, from $265,718 for the quarter

ended December 31, 2008. R&D expenses also decreased as a percentage of net

sales for the quarter ended December 31, 2009, to 2.4 % from 3.0% of net sales

for the quarter ended December 31, 2008. R&D expenses decreased $104,897, or

19.9%, to $422,850 for the six months ended December 31, 2009, from $527,747 for

the six months ended December 31, 2008. R&D costs are expensed as incurred. We

expect to continue our commitment to developing innovative products for the

physical medicine market in fiscal year 2010 and in future periods in order to

position us for growth. We anticipate that R&D expenses as a percentage of net

sales and in absolute terms will increase modestly over the coming quarters

based on the schedule of new products currently under development. Current year

decreases reflect a strategy shift to outsourcing some R&D functions, thus

eliminating some personnel costs.



Net income increased to $188,299, or $.01 per share, for the quarter ended

December 31, 2009, compared to $54,598, or $.00 per share, for the quarter ended

December 31, 2008. Net income increased to $256,923, or $.02 per share, for the

six months ended December 31, 2009, compared to a net loss of $84,353, or ($.01

per share), for the six months ended December 31, 2008. The main factors

contributing to the improvement in net income for the quarter and six months

ended December 31, 2009 were the reduction in SG&A expenses and lower R&D and

interest expenses.



The outstanding balance on our line of credit with a bank decreased

$263,899, to $4,338,752 as of December 31, 2009, compared to $4,602,651 as of

June 30, 2009, and $6,208,338 as of December 31, 2008. Interest on the line of

credit is based on the 90-day LIBOR rate (0.25% as of December 31, 2009) plus 4%

with a minimum interest rate of 4.5% per annum. The line of credit is

collateralized by accounts receivable and inventories, as well as a security

interest in our headquarters facility in Cottonwood Heights, Utah. Borrowing

limitations are based on approximately 45% of eligible inventory and up to 80%

of eligible accounts receivable, up to a maximum credit facility of $7,000,000.

Interest payments on the line are due monthly. As of December 31, 2009, the

borrowing base was approximately $6,177,000, resulting in approximately

$1,800,000 available on the line. The line of credit is renewable in December

2010 and includes covenants requiring us to maintain certain financial ratios.

As of December 31, 2009, we were in compliance with the loan covenants.



Any modifications to estimates of inventory valuation reserves are

reflected in cost of goods sold within the statements of operations during the

period in which such modifications are determined necessary by management. As of

December 31, 2009 and June 30, 2009, our inventory valuation reserve balance,

which established a new cost basis, was $425,539 and $338,788, respectively, and

our inventory balance was $5,971,500 and $6,199,251, net of reserves,

respectively.



Read the The complete Report

About the author:

10qk
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 3.8/5 (4 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK